MREO
Price
$1.77
Change
-$0.01 (-0.56%)
Updated
Jul 18 closing price
Capitalization
281.43M
79 days until earnings call
SAVA
Price
$2.21
Change
+$0.11 (+5.24%)
Updated
Jul 18 closing price
Capitalization
106.76M
10 days until earnings call
Interact to see
Advertisement

MREO vs SAVA

Header iconMREO vs SAVA Comparison
Open Charts MREO vs SAVABanner chart's image
Mereo BioPharma Group
Price$1.77
Change-$0.01 (-0.56%)
Volume$2.37M
Capitalization281.43M
Cassava Sciences
Price$2.21
Change+$0.11 (+5.24%)
Volume$1.55M
Capitalization106.76M
MREO vs SAVA Comparison Chart in %
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. SAVA commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and SAVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (MREO: $1.77 vs. SAVA: $2.21)
Brand notoriety: MREO and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 99% vs. SAVA: 136%
Market capitalization -- MREO: $281.43M vs. SAVA: $106.76M
MREO [@Biotechnology] is valued at $281.43M. SAVA’s [@Biotechnology] market capitalization is $106.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileSAVA’s FA Score has 1 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • SAVA’s FA Score: 1 green, 4 red.
According to our system of comparison, SAVA is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 5 TA indicator(s) are bullish while SAVA’s TA Score has 6 bullish TA indicator(s).

  • MREO’s TA Score: 5 bullish, 5 bearish.
  • SAVA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than MREO.

Price Growth

MREO (@Biotechnology) experienced а +9.94% price change this week, while SAVA (@Biotechnology) price change was +3.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

MREO is expected to report earnings on Oct 07, 2025.

SAVA is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MREO($281M) has a higher market cap than SAVA($107M). SAVA YTD gains are higher at: -6.356 vs. MREO (-49.429). MREO has higher annual earnings (EBITDA): -44.87M vs. SAVA (-145.89M). SAVA has more cash in the bank: 117M vs. MREO (62.5M). SAVA has less debt than MREO: SAVA (0) vs MREO (747K). MREO (0) and SAVA (0) have equivalent revenues.
MREOSAVAMREO / SAVA
Capitalization281M107M263%
EBITDA-44.87M-145.89M31%
Gain YTD-49.429-6.356778%
P/E RatioN/AN/A-
Revenue00-
Total Cash62.5M117M53%
Total Debt747K0-
FUNDAMENTALS RATINGS
MREO vs SAVA: Fundamental Ratings
MREO
SAVA
OUTLOOK RATING
1..100
5517
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9554
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (22) in the Pharmaceuticals Other industry is somewhat better than the same rating for MREO (71) in the null industry. This means that SAVA’s stock grew somewhat faster than MREO’s over the last 12 months.

SAVA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MREO (100) in the null industry. This means that SAVA’s stock grew similarly to MREO’s over the last 12 months.

SAVA's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as MREO (98) in the null industry. This means that SAVA’s stock grew similarly to MREO’s over the last 12 months.

SAVA's Price Growth Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for MREO (95) in the null industry. This means that SAVA’s stock grew somewhat faster than MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for SAVA (100) in the Pharmaceuticals Other industry. This means that MREO’s stock grew significantly faster than SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREOSAVA
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SRUUF16.250.04
+0.25%
Sprott Physical Uranium Trust
PVTRF0.92N/A
N/A
PIVOTREE INC. New
LKREF5.38N/A
N/A
Link Real Estate Investment Trust
NRWRF0.97N/A
N/A
Newriver Reit Plc
DLMI10.26-0.24
-2.28%
Diamond Lake Minerals, Inc.

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-0.56%
RARE - MREO
65%
Loosely correlated
-4.01%
TRDA - MREO
47%
Loosely correlated
-1.88%
NRIX - MREO
41%
Loosely correlated
-7.28%
CRNX - MREO
39%
Loosely correlated
-5.78%
KYMR - MREO
34%
Loosely correlated
-0.37%
More

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with PRRUF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then PRRUF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
+5.24%
PRRUF - SAVA
33%
Loosely correlated
N/A
OMER - SAVA
25%
Poorly correlated
-3.45%
CMPX - SAVA
23%
Poorly correlated
-4.76%
MREO - SAVA
22%
Poorly correlated
-0.56%
RARE - SAVA
22%
Poorly correlated
-4.01%
More